Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Nanologica AB ( (SE:NICA) ) is now available.
Nanologica AB has secured its first North American order for its silica-based purification media, NLAB Saga®, from a US-based peptide drug manufacturer. This order, valued at approximately SEK 1.3 million, marks a significant entry into the North American market, complementing the company’s existing focus on Asian markets, particularly China. The order will be delivered in the third quarter and represents a strategic expansion for Nanologica, potentially enhancing its market positioning and stakeholder value.
More about Nanologica AB
Nanologica AB is a Swedish life science tools company that specializes in developing, manufacturing, and selling advanced consumables for pharmaceutical manufacturers. Their silica-based products are designed for the purification of peptide drugs, such as insulin and GLP-1 analogues, which help increase productivity and reduce costs for pharmaceutical companies. The company operates in a growing global niche market driven by the rising demand for diabetes and obesity treatments, aiming to enhance access to cost-effective medicines worldwide. Nanologica is headquartered in Södertälje and is listed on the Nasdaq Stockholm Main Market.
Average Trading Volume: 340,449
Current Market Cap: SEK99.84M
See more data about NICA stock on TipRanks’ Stock Analysis page.